Nefrosave Dosing and Management in Acute Kidney Injury

Introduction to Nefrosave Management

• The Blood Cancer Journal recommends that medications like lenalidomide require significant dose reductions in renal impairment, but Nefrosave does not have such restrictions in its labeling 1

Critical Monitoring and Safety Considerations

• The Kidney International and Clinical Nutrition guidelines suggest that AKI severity should be staged according to KDIGO criteria to guide overall management, with stages defined as: Stage 1: creatinine 1.5-1.9× baseline; Stage 2: 2.0-2.9× baseline; Stage 3: ≥3.0× baseline or creatinine ≥4.0 mg/dL or initiation of dialysis 3, 4

Nephrotoxic Medication Management

• The Kidney International and Blood Cancer Journal guidelines recommend that renally excreted drugs should be temporarily discontinued in patients with GFR <60 mL/min/1.73 m² who have serious intercurrent illness increasing AKI risk, and that medications like Nefrosave should be administered with caution in patients with AKI 1, 3